Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney transplant drug switch under study

NCT ID NCT05193565

Ongoing Disease control Sponsor: Chong Kun Dang Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether switching kidney transplant patients from their current maintenance drugs to either RaparoBell® or Myrept® is safe and effective. About 206 adults who had a kidney transplant 1-10 years ago are taking part. The goal is to see if the new drugs prevent rejection and graft loss as well as the standard therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sirolimus (RaparoBell®) and Mycophenolate mofetil (Myrept®)
What this could lead to
If successful, this could show that switching to these drugs is a safe and effective option for long-term kidney transplant maintenance.
What could go wrong
This is a mid-stage trial with 206 participants, so results may not apply to all patients. Risks include rejection, graft loss, or side effects from the new drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.